Posted by Michael Wonder on 30 Mar 2020
Lilly's Taltz (ixekizumab) receives U.S. FDA approval for the treatment of paediatric patients with moderate to severe plaque psoriasis
30 March 2020 - Taltz is the first and only IL-17A antagonist approved to treat this population.
Eli Lilly announced today the U.S. FDA has approved a supplemental biologics license application for Taltz (ixekizumab) injection, 80 mg/mL for the treatment of paediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The safety, tolerability and efficacy of Taltz in patients ages 6 to under 18 was demonstrated in a randomised, double-blind, placebo-controlled Phase 3 study that included 171 patients with moderate to severe plaque psoriasis.
